Fingerprint
Dive into the research topics of 'A phase i study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically